Bellerophon Therapeutics (BLPH)
(Delayed Data from OTC)
$0.04 USD
0.00 (0.00%)
Updated Aug 6, 2024 11:56 AM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Bellerophon Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 7 | 25 | 48 | 10 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 0 | 1 | 0 | 0 |
Total Current Assets | NA | 8 | 25 | 48 | 10 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 8 | 27 | 50 | 13 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 1 | 4 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 4 | 3 | 6 | 4 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 5 | 5 | 10 | 8 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 1 | 0 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 5 | 5 | 12 | 10 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 255 | 254 | 253 | 193 |
Retained Earnings | NA | -252 | -232 | -214 | -190 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 3 | 22 | 38 | 4 |
Total Liabilities & Shareholder's Equity | NA | 8 | 27 | 50 | 13 |
Total Common Equity | 0 | 3 | 22 | 38 | 4 |
Shares Outstanding | 12.20 | 9.50 | 9.50 | 9.50 | 4.50 |
Book Value Per Share | 0.00 | 0.27 | 2.28 | 4.03 | 0.80 |
Fiscal Year End for Bellerophon Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | -99,999 | 4 | 11 |
Receivables | NA | NA | NA | 0 | 0 |
Notes Receivable | NA | NA | NA | 0 | 0 |
Inventories | NA | NA | NA | 0 | 0 |
Other Current Assets | NA | NA | NA | 0 | 1 |
Total Current Assets | NA | NA | NA | 5 | 11 |
Net Property & Equipment | NA | NA | NA | 0 | 0 |
Investments & Advances | NA | NA | NA | 0 | 0 |
Other Non-Current Assets | NA | NA | NA | 0 | 0 |
Deferred Charges | NA | NA | NA | 0 | 0 |
Intangibles | NA | NA | NA | 0 | 0 |
Deposits & Other Assets | NA | NA | NA | 0 | 0 |
Total Assets | NA | NA | NA | 5 | 11 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | 0 | 0 |
Accounts Payable | NA | NA | NA | 1 | 2 |
Current Portion Long-Term Debt | NA | NA | NA | 0 | 0 |
Current Portion Capital Leases | NA | NA | NA | 0 | 0 |
Accrued Expenses | NA | NA | NA | 1 | 4 |
Income Taxes Payable | NA | NA | NA | 0 | 0 |
Other Current Liabilities | NA | NA | NA | 0 | 0 |
Total Current Liabilities | NA | NA | NA | 1 | 6 |
Mortgages | NA | NA | NA | 0 | 0 |
Deferred Taxes/Income | NA | NA | NA | 0 | 0 |
Convertible Debt | NA | NA | NA | 0 | 0 |
Long-Term Debt | NA | NA | NA | 0 | 0 |
Non-Current Capital Leases | NA | NA | NA | 0 | 0 |
Other Non-Current Liabilities | NA | NA | 0 | 0 | |
Minority Interest (Liabilities) | NA | NA | NA | 0 | 0 |
Total Liabilities | NA | NA | NA | 1 | 6 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | 0 | 0 |
Common Stock (Par) | NA | NA | NA | 0 | 0 |
Capital Surplus | NA | NA | NA | 260 | 260 |
Retained Earnings | NA | NA | NA | -256 | -254 |
Other Equity | NA | NA | NA | 0 | 0 |
Treasury Stock | NA | NA | NA | 0 | 0 |
Total Shareholder's Equity | NA | NA | NA | 4 | 6 |
Total Liabilities & Shareholder's Equity | NA | NA | NA | 5 | 11 |
Total Common Equity | 0 | 0 | 0 | 4 | 6 |
Shares Outstanding | 12.20 | 12.20 | 12.20 | 12.20 | 10.40 |
Book Value Per Share | 0.00 | 0.00 | 0.00 | 0.30 | 0.54 |